You are here: Industry Insights > ADC

News List

Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients prnasia
February 25, 2021
Genome & Company today announced having entered into a research collaboration for the discovery of innovative cancer therapies in the expanding antibody-drug conjugates (ADC) class.
Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage prnasia
February 01, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has ...
BrickBio Inks ADC Co-Development Deal contractpharma
January 07, 2021
BrickBio, a company specializing in site-specific bioconjugation for improved therapeutics, has signed an agreement with a large pharmaceutical company to co-develop a therapeutic antibody drug conjugate (ADC).
Lantern Pharma Launches ADC Program contractpharma
January 05, 2021
Lantern Pharma, a clinical-stage biopharma company using its RADR artificial intelligence platform to advance cancer drug development, is launching the development of its ADC (Antibody Drug Conjugate) program through an evaluation and potential ...
PPF Group Sells Sake in NBE-Therapeutics to Boehringer Ingelheim americanpharmaceuticalreview
December 31, 2020
PPF Group has announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) ...
Boehringer to Acquire NBE-Therapeutics in €1.2B Transaction contractpharma
December 11, 2020
PPF Group, an international investment group, has signed an agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim.
Lonza Enters Long-term Bioconjugation Collaboration contractpharma
December 03, 2020
Will construct two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates at its Visp site.
Abenza Upgrades Chemistry GMP Suites contractpharma
November 25, 2020
Abzena, a global partner research organization for integrated bench to market solutions for biologics and bioconjugates, has announced upgrades of its chemistry GMP suites.
Lonza Opens Facility for ADC Payload Manufacturing contractpharma
November 06, 2020
Lonza, a specialty CDMO partner to the biopharma industry, has inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at the Visp, Switzerland site.
Samsung Biologics Expands in China contractpharma
November 05, 2020
Samsung Biologics has entered into a partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC)...

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page